health canada approval zepbound tirzepatide obesity canada date Zepbound® — A New Treatment for FDA approval for Zepbound (tirzepatide)

BPC-157 for Endometriosis Pain Management BPC-157 demonstrates significant potential for endometriosis treatment through its powerful anti-inflammatory and healing properties

Last week, Gilead abandoned another drug (ziritaxestat) it was developing under the deal

In the first 20 weeks of treatment, participants had lost an average of 10% of their body weight, and 15% of their body weight in just over a year of treatment (68 weeks)

Semaglutidesold under the brand name Ozempic for type 2 diabetes and as Wegovy for chronic weight managementhas surged in use for its effects on blood sugar control, appetite suppression, and modest weight loss

Supplementary material The Supplementary Material for this article can be found online at: References 1 ArnoldL

CrandallBairdClevelandOhio - Cleveland Area$1M$1B$5-10M$2-5MJeremy BaynesWells Fargo AdvisorsHudsonOhio - Cleveland Area$500K$564M$500K-12M$500K-12MScott GehlbachMerrill Wealth ManagementWestlakeOhio - Cleveland Area$500K$9.1B$3-7M$1-8MKirk HunterMerrill Wealth ManagementCantonOhio - Cleveland Area$500K$349M$1-10M$2-5MKelly S